Oncolytics Biotech Inc.
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-22
Oncolytics Biotech to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
News release - English.pdf
Results 2026-05-14
Interim MD&A - English.pdf
Results 2026-05-14
Interim financial statements/report – English.pdf
Results 2026-05-04
Oncolytics Biotech® Reports Durable Clinical Activity in Metastatic Colorectal Cancer with 19.5-Month Median Duration of Response and 100% Disease Control in Late-Line Patients
News release - English.pdf
News 2026-04-27
Oncolytics Biotech Announces FDA Alignment on Pivotal Study Design for Pelareorep in Anal Cancer
News release - English.pdf
News 2026-04-06
Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
News release - English.pdf
Transactions 2026-04-01 Financing
Other material contracts - English.pdf
Transactions 2026-04-01 Financing
Other material contracts - English.pdf
Transactions 2026-04-01 Financing
Other material contracts - English.pdf
Transactions 2026-04-01 Financing
Other material contracts - English.pdf
Ownership 2026-04-01
Other securityholders documents - English.pdf
Results 2026-03-30
Annual report on form 10-K - English.pdf
Results 2026-03-30
Annual MD&A - English.pdf
Results 2026-03-30
Audited annual financial statements – English.pdf
Results 2026-03-30
Interim MD&A (amended) - English.pdf
Results 2026-03-30
Interim financial statements/report (amended) - English.pdf
Results 2026-03-30
Interim MD&A (amended) - English.pdf
Results 2026-03-30
Interim financial statements/report (amended) - English.pdf
Results 2026-03-30
Interim MD&A (amended) - English.pdf
Results 2026-03-30
Interim financial statements/report (amended) - English.pdf
News 2026-03-20
Other securityholders documents - English.pdf
News 2026-03-19
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
News release - English.pdf
News 2026-03-18
Certificate and Articles of Incorporation.pdf
News 2026-03-18
Certificate and Articles of Incorporation.pdf
News 2026-03-02
Oncolytics Biotech Launches Randomized Colorectal Cancer Study
News release - English.pdf
Results 2026-02-24
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
News release - English.pdf
Ownership 2026-02-13
5 insiders · +$148k net
Insider trading – 2026-02-13
5 insiders · +$148k net
News 2026-02-04
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
News release - English.pdf
Ownership 2026-01-20
Seizinger, Bernd Robert bought +$104k
Insider trading – 2026-01-20
1 insider · +$104k net
Results 2026-01-12
Oncolytics Biotech Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
News release - English.pdf
News 2026-01-08
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
News release - English.pdf
Results 2025-12-16
Oncolytics Biotech Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
News release - English.pdf
News 2025-12-09
Other.pdf
News 2025-12-09
Other.pdf
Transactions 2025-12-09 M&A
Oncolytics Biotech Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
News release - English.pdf
News 2025-12-05
Other.pdf
News 2025-11-19
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
News release - English.pdf
News 2025-11-17
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
News release - English.pdf
Results 2025-11-12 Financials
Interim MD&A - English.pdf
Results 2025-11-12 Financials
Interim financial statements/report – English.pdf
News 2025-10-28
Material change report - English.pdf
News 2025-10-28
News release - English.pdf
News 2025-10-20
News release - English.pdf
News 2025-10-20
Other.pdf
News 2025-10-20
Other.pdf
News 2025-09-29
News release - English.pdf
News 2025-09-16
News release - English.pdf
News 2025-09-08
News release - English.pdf
News 2025-09-02
News release - English.pdf
News 2025-08-28
News release - English.pdf
News 2025-08-11
News release - English.pdf
Results 2025-08-08 Financials
Interim MD&A - English.pdf
Results 2025-08-08 Financials
Interim financial statements/report – English.pdf
News 2025-08-08
News release - English.pdf
News 2025-08-08
News release - English.pdf
News 2025-08-05
News release - English.pdf
News 2025-07-29
News release - English.pdf
News 2025-07-23
News release - English.pdf
News 2025-07-22
News release - English.pdf
Ownership 2025-07-18
Hagerman, Allison bought +$8k
Insider trading – 2025-07-18
1 insider · +$8k net
Ownership 2025-07-17
Look, Kirk bought +$15k
Insider trading – 2025-07-17
1 insider · +$15k net
News 2025-07-16
News release - English.pdf
News 2025-07-10
News release - English.pdf
News 2025-07-08
News release - English.pdf
News 2025-06-30
News release - English.pdf
News 2025-06-11
News release - English.pdf